Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 1, Issue 2, Pages 64-75Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2011.11.001
Keywords
Cannabis; Endocannabinnoid; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroprotection; Spasticity
Categories
Funding
- GW Pharma Ltd.
Ask authors/readers for more resources
Cannabis-based medicines have recently been approved for the treatment of pain and spasticity in multiple sclerosis (MS). This supports the original perceptions of people with MS, who were using illegal street cannabis for symptom control and pre-clinical testing in animal models of MS. This activity is supported both by the biology of the disease and the biology of the cannabis plant and the endocannabinoid system. MS results from disease that impairs neurotransmission and this is controlled by cannabinoid receptors and endogenous cannabinoid ligands. This can limit spasticity and may also influence the processes that drive the accumulation of progressive disability. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available